Diagnosing Giant Cell Arteritis (GCA): Key Steps You Need to Know!


#GiantCellArteritis #MedEd #USMLE #USMLEStep1 #USMLEStep2

This case shows optic nerve sheath enhancement on MRI as an unusual clue, with rapid improvement after early steroids. Would you treat GCA empirically based on this finding?

Read more: www.cureus.com/articles/407...

#Cureus #Neurology #Rheumatology #GiantCellArteritis #MedSky

Research Article

Assessment of Giant Cell Arteritis–Associated Visual Outcomes at a Tertiary Hospital in Ontario, Canada

📖 www.jrheum.org/cgi/content/...
@matsjunek.bsky.social @rahulchanchlani.bsky.social @macdeptmed.bsky.social

#GiantCellArteritis #Vasculitis #Glucocorticoids

Fibromyalgia

Here's a page I put together to help friends and family understand #Fibromyalgia, one of my wife's comorbidities. Others include #Haemochromatosis #GiantCellArteritis, and #BrainInjury

Thanks Meredith. Twenty years ago I had never heard of #Hemochromatosis, #Fibromyalgia, #GiantCellArteritis or #Comorbidities. It's been quite the journey.

Vision Loss in Giant Cell Arteritis Remains Common Despite Glucocorticoid Therapy Disease-associated vision changes are common in GCA, with no significant difference in visual improvement observed with IV glucocorticoids vs oral therapy.

Vision loss still occurs frequently in Giant Cell Arteritis, even with glucocorticoid treatment:
www.optometryadvisor.com/news/vision-...
#GiantCellArteritis #VisionLoss #Rheumatology #GCA #Ophthalmology #MedicalResearch

📅 Mark your calendars: October 23 is #GCAAwarenessDay. Giant Cell Arteritis can cause sudden vision loss — but awareness saves sight. 👁️💡
#GiantCellArteritis #StopVisionLoss #PatientAdvocacy

#GiantCellArteritis is an inflammatory condition that affects the blood vessels, particularly those in the head and neck. If left untreated, it can lead to serious complications.
Learn more: arthritisaustralia.com.au/types-of-art...

#ArthritisAustralia #WorldArthritisDay #WorldArthritisDay2025

New #CME on #GiantCellArteritis highlights the importance of early diagnosis and sustained remission to prevent blindness, stroke, and relapse. Including updates on imaging, diagnostics, and targeted biologics.

Enroll for free at
@medliveofficial
: 🩺 bit.ly/46cSDML

Upadacitinib: A (r)evolution in the management of GCA?

Further discussions on the role #upadacitinib will likely play in the therapeutic landscape of #giantcellarteritis treatment.
#medsky #rheumsky

🔗www.sciencedirect.com/science/article/abs/pii/...

The Efficacy and Safety of Leflunomide in the Treatment of Giant Cell Arteritis: A Protocol for a Systematic Review
J.-P., Makhzoum et al.
Paper
Details
#LeflunomideReview #GiantCellArteritis #SystematicReview

Research Article

Delays in Tocilizumab Therapy for Patients With Giant Cell Arteritis in the United States

📖 www.jrheum.org/cgi/content/...
@dfeterman.bsky.social @alisonbays.bsky.social @rheumcat.bsky.social @uwdeptmedicine.bsky.social

#giantcellarteritis #vasculitis

Editorial

Does Prior Authorization for Tocilizumab Lead to Unacceptable Treatment Delays in Giant Cell Arteritis?

📖 doi.org/10.3899/jrhe...
@westernu.ca

#giantcellarteritis #vasculitis

Novartis drug flunks phase 3 test in giant cell arteritis Novartis hopes of bringing Cosentyx to patients with giant cell arteritis seem to be over after the drug missed all the endpoints in a phase 3 trial.

#Novartis' blockbuster immunology drug #Cosentyx has disappointed in a phase 3 trial involving patients with #giantcellarteritis, a debilitating #autoimmunedisease affecting the arteries.

pharmaphorum.com/news/novarti...

Novartis Cosentyx fails in late-stage giant cell arteritis trial Investing.com -- Novartis (SIX:NOVN) announced Thursday that its Cosentyx drug did not meet its primary goal in a Phase III trial for adults with giant cell arteritis (GCA). The drug failed to demonstrate an improvement in sustained remission among patients with newly diagnosed or relapsing GCA, according to the Swiss pharmaceutical company. Shreeram Aradhye, president of development and chief medical officer at Novartis, said: "While the Phase III results did not replicate the positive outcomes observed in the Phase II trial, we remain committed to continuing to drive scientific progress and deepening the understanding of immune-mediated diseases." This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Click Subscribe #Novartis #Cosentyx #GiantCellArteritis #ClinicalTrials #PharmaceuticalNews

AbbVie’s Rinvoq receives EC approval to treat adults with giant cell arteritis - PMLiVE The drug is now the first oral JAK inhibitor to be approved in the EU for this patient population

#AbbVie #Rinvoq #upadacitinib #giantcellarteritis #oralJAKinhibitor #JAKinhibitor #marketingauthorisation #Januskinaseinhibitor #SELECTGCAtrial #immunology #pharma #pharmaceuticals
zurl.co/ovP8I

SGCAPS - RheumMadness Team: Ultrasound Avengers / Halo Heroes Base article: Sebastian A, van der Geest KSM, Tomelleri A, Macchioni P, Klinowski G, Salvarani C, Prieto-Peña D, Conticini E, Khurshid M, Dagna L, Brouwer E, Da...

Only 1.5 days left to submit your #RheumMadness bracket!

Next up on our countdown: SGCAPS + MSKUS prediction tool for #giantcellarteritis, by fellows from MCW.

Read it here:
sites.duke.edu/rheummadness...

Research Article

Tocilizumab (TCZ) for Giant Cell Arteritis: Clinical Outcomes Following Relapses and TCZ Discontinuation Due to Adverse Events

📖 www.jrheum.org/cgi/content/...

#giantcellarteritis #vasculitis #glucocorticoids #tocilizumab

Editorial

Managing Giant Cell Arteritis With Tocilizumab: Relapses and Adverse Events

📖 www.jrheum.org/cgi/content/...

#giantcellarteritis #tocilizumab

Risk loci (HLA & more) for #GiantCellArteritis

GWAS 3498 case + 15550 Ctrl, 10 cohorts/countries

An 11-SNP #PolygenicRiskScore for GCA

rs704, a missense VTN/vitronectin variant
rs8029053 MFGE8▶️#Vasculitis #Amyloidosis?😁

#LancetRheum 2024
www.sciencedirect.com/science/arti...